Diabetic Peripheral Neuropathy is a devious, chronic nerve damage adding to the litany of diabetes’ effects.
An Italian specialty pharmaceutical company – based out of Louisiana – sought to devise a new treatment quickly.
Using the chosen sites’ robust databases of diabetes subjects, print advertising, email blasts, and local outreach, the Phase IV study was set up fast.
After two years, the 25 subjects – 17 more than the enrollment goal – brought the study to a successful close with a 92% retention rate.
Though the symptoms of DPN can be difficult to diagnose – a complication for any study – we’re one step closer to understanding it.